Sionna Therapeutics (SION) news
Recent news
Sionna Therapeutics, - Board approves workforce reduction of about 46% and implements cost-saving measures
Sionna Therapeutics, Inc. has announced that its board of directors has approved a significant workforce reduction, affecting approximately 46% of its current employees. The move is part of a broader strategy to implement cost-saving measures and improve operational efficiency amid ongoing…
AInvest Wire · Sep 14, 2026Sionna Therapeutics announces plans to advance Sion-451 + Sion-2222 dual combination into phase 2A proof-of-concept trial
AInvest Wire · Sep 14, 2026Wedbush cuts Sionna Therapeutics to neutral from outperform; cuts target price to $5 from $53
Wedbush Securities has revised its stance on Sionna Therapeutics (NASDAQ:SION), downgrading the stock from Outperform to Neutral and significantly lowering its price target to $5 from $53. The adjustment follows evolving expectations regarding the company’s clinical development timeline and data…
AInvest Wire · Aug 11, 2026RBC raises Sionna Therapeutics to sector perform from underperform; cuts target price to $5 from $23
AInvest Wire · Aug 10, 2026Sionna Therapeutics shares down 91% after co's experimental drug misses mid-stage trial goal
AInvest Wire · Aug 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.